

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alain MOUSSY et al.
Title: 2-(3-SUBSTITUTED-ARYL) AMINO-4-
ARYL-THIAZOLES AS TYROSINE KINASE
INHIBITORS
Appl. No.: Unassigned
International Filing Date: 1/28/2005
371(c) Date:
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. Copies of the cited references listed in the Search Report are not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Michael M. Maebius
Reg No. 34,717

By _____

Date July 26, 2006

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

for

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: July 26, 2006 <i>(use as many sheets as necessary)</i>				Complete if Known Application Number Unassigned Filing Date 1/28/2005 First Named Inventor Alain Moussy Group Art Unit Unassigned Examiner Name Unassigned Attorney Docket Number 065691-0457	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	WO	03/004467	A	Agouron Pharmaceuticals, Inc.	01/16/2003		
	A2	WO	03/062215	A	Kylux Pharmaceuticals B.V.	07/31/2003		
	A3	WO	2004/014903	A	AB Science	02/19/2004		
	A4	WO	2005/000298	A	Triad Therapeutics, Inc.	01/06/2005		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A5	Database Bielstein Beilstein Institute for Organic Chemistry, XP002328977, Database accession no. BRN: 260633 abstract & Yakugaku Zasshi, vol. 75, 1955, p. 1082.	
	A6	Database Bielstein Beilstein Institute for Organic Chemistry, XP002328978, Database accession no. BRN: 7227176 abstract & J. Indian Chem. Soc., vol. 71, no. 4, 1994, pp. 205-208.	
	A7	Database Bielstein Beilstein Institute for Organic Chemistry, XP002328979, Database accession no. BRN: 5076163 abstract & Indian J. Chem. Sect. B, vol. 26, no. 1-12, 1987, pp. 856-860.	
	A8	Database Bielstein Beilstein Institute for Organic Chemistry, XP002328980, Database accession no. BRN: 3761233 abstract & Yakugaku Zasshi, vol. 75, 1955, p. 1077.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.